SCHEMBL3093756

SCHEMBL3093756

CCN(C(=O)C(CCCc1ccc2ccccc2c1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.46
TPSAB1 Q15661 2/20 0.41
LMNA P02545 1/20 0.41
F2 P00734 2/20 0.40
ALDH1A1 P00352 3/20 0.40
TBXAS1 P24557 1/20 0.40
CYP1A2 P05177 1/20 0.40
KDM4E B2RXH2 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
POLB P06746 1/20 0.39
CNR2 P34972 1/20 0.39
SLC16A3 O15427 1/20 0.39
RAPGEF3 O95398 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3100295 0.94 LARS1 (0.47) LARS1TPSAB1LMNAF2ALDH1A1
SCHEMBL3093369 0.94 LARS1 (0.44) LARS1TPSAB1LMNAF2ALDH1A1
SCHEMBL3080463 0.93 LARS1 (0.43) LARS1TPSAB1LMNAF2ALDH1A1
SCHEMBL3093531 0.92 ALDH1A1 (0.51) LARS1TPSAB1LMNAALDH1A1KDM4E
SCHEMBL3090337 0.89 POLB (0.44) LARS1TPSAB1LMNAALDH1A1KDM4E
SCHEMBL3100686 0.89 TBXAS1 (0.55) LARS1LMNATBXAS1HPGD
SCHEMBL3093370 0.88 LARS1 (0.45) LARS1TPSAB1LMNAF2ALDH1A1
SCHEMBL3089594 0.87 LARS1 (0.47) LARS1TPSAB1LMNAF2ALDH1A1
SCHEMBL3096411 0.87 LARS1 (0.45) LARS1TPSAB1LMNAF2ALDH1A1
SCHEMBL3090585 0.86 ALDH1A1 (0.52) LARS1LMNAALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885TPSAB1 1070/4885LMNA 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.